EGFR and head and neck squamous cell carcinoma: In summary, the results demonstrate a wide range of EGFR/ERBB inhibitor-induced interferon program activation in human and murine HNSCC cell lines and support the hypothesis that this transcriptional response variably instructs participation of the immune microenvironment in the overall therapeutic response.